Teknova to Report Third Quarter 2022 Financial Results on November 9, 2022
Alpha Teknova, Inc. (Nasdaq: TKNO) will report its third quarter financial results for the period ending September 30, 2022, on November 9, 2022. A conference call and webcast will follow at 4:30 p.m. ET, accessible via the company’s Investor Relations page. Teknova specializes in providing critical reagents for drug therapies and diagnostics, emphasizing agility and customization in delivering high-quality products. The company's offerings include cell culture media and purification buffers for various applications, such as mRNA therapeutics and genomics.
- None.
- None.
HOLLISTER, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2022, on Wednesday, November 9, 2022, following the close of market.
Teknova will host a webcast and conference call on Wednesday, November 9, 2022, beginning at 4:30 p.m. ET. Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/rjjxxr67. To receive a PIN number for dial in, participants can register for the webcast via this link: https://register.vevent.com/register/BIc8c72fb8e9214c49b689933915e724ad. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Teknova
Teknova is expediting clinical breakthroughs in life sciences by providing custom products and reagents for drug therapies, novel vaccines, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products, including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high-quality, custom, made-to-order products with short turnaround times and at scale across all stages of development, including commercialization.
FAQ
When will Teknova report its financial results for Q3 2022?
What time is the Teknova Q3 2022 conference call?
Where can I watch the Teknova Q3 2022 earnings call?
What is Teknova's focus in the life sciences field?
